CSL Limited (FRA:CSJA)

Market Cap	50.67B
Revenue (ttm)	13.25B
Net Income (ttm)	2.56B
Shares Out	n/a
EPS (ttm)	5.25
PE Ratio	19.82
Forward PE	17.34
Dividend	1.20 (2.40%)
Ex-Dividend Date	Sep 10, 2025

Volume	n/a
Average Volume	1
Open	51.00
Previous Close	51.00
Day's Range	51.00 - 51.00
52-Week Range	47.60 - 85.50
Beta	n/a
RSI	50.01
Earnings Date	Feb 9, 2026

About CSL Limited

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascul...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1916
• Employees: 29,904
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CSJA

Financial Performance

In 2025, CSL Limited's revenue was $15.56 billion, an increase of 5.12% compared to the previous year's $14.80 billion. Earnings were $3.00 billion, an increase of 13.63%.

Financial numbers in USD